Back to the main directory
EarningsReview / Equity
- Strong beat by costs, provisions and taxes. 25-28 ambitions set by BNP Paribas Exane
- Q2-25 Final results. First Take by BNP Paribas Exane
- Q2'25 results: Solid but underwhelming guidance “upgrade” by BNP Paribas Exane
- Results Flash - Q2 in-line, asset failure brings significant Q3 downside risk by BNP Paribas Exane
- Q2 first take: Strong order intake; mgmt. sees lower end of guidance by BNP Paribas Exane
- Figures in line, FCF impacted by WC, Guidance narrowed by BNP Paribas Exane
- Approaching Margin U-Turn by BNP Paribas Exane
- Q2’25 slightly worse than feared (esp FCF), but FY cons largely there by BNP Paribas Exane
- Earnings miss on Project delivery segment, TPS margin guidance raised by BNP Paribas Exane
- 1H25 First take - small beat at NI by BNP Paribas Exane
- 1H25 first take: Q2 EBITDA 8% miss, full year downgrades likely by BNP Paribas Exane
- Q2 results first take: cat already out the bag by BNP Paribas Exane
- Beat on execution; guidance maintained by BNP Paribas Exane
- VISCOFAN: RDOS. 2T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- 1H25 first take - Underlying EBITDA ahead, divi light, no further update on portfolio simplification by BNP Paribas Exane
- Q2’25 first take: Mostly in line, N.Am pest organic improved in Q2 by BNP Paribas Exane
- Fluidra - Guidance narrowed to the low end was expected; Neutral by JB Capital Markets
- Solid Shell 2Q25 Results and cash flow. Buy-back held at USD3.5bn by BNP Paribas Exane
- SOCIÉTÉ GÉNÉRALE: RDOS. 2T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- 2Q25 Results - Somatuline once again to the rescue by BNP Paribas Exane
- Results Flash - Q2 EBITDA beat, FCF in-line, Q3 downside risk by BNP Paribas Exane
- Beyfortus/Altuviiio commentary from Sanofi by BNP Paribas Exane
- HRS - HRS aborde FY26 avec un carnet de commandes assaini by MidCap Partners
- MedinCell - Révision en hausse des ambitions côté Teva by MidCap Partners
- ICAPE HOLDING - La reprise se confirme ! by MidCap Partners